Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients

Kimie Sai,Yoshiro Saito,Keiko Maekawa,Su-Ryang Kim,Nahoko Kaniwa,Tomoko Nishimaki-Mogami,Jun-ichi Sawada,Kuniaki Shirao,Tetsuya Hamaguchi,Noboru Yamamoto,Hideo Kunitoh,Yuichiro Ohe,Yasuhide Yamada,Tomohide Tamura,Teruhiko Yoshida,Yasuhiro Matsumura,Atsushi Ohtsu,Nagahiro Saijo,Hironobu Minami
DOI: https://doi.org/10.1007/s00280-009-1138-y
Abstract:Purpose: Effects of genetic polymorphisms/variations of ABCB1, ABCC2, ABCG2 and SLCO1B1 in addition to "UGT1A1*28 or *6" on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients were investigated. Methods: Associations between transporter haplotypes/variations along with UGT1A1*28 or *6 and SN-38 area under the time-concentration curve (AUC) or neutropenia were examined in irinotecan monotherapy (55 patients) and irinotecan-cisplatin-combination therapy (62 patients). Results: Higher SN-38 AUC values were observed in ABCB1 2677G>T (A893S) (*2 group) for both regimens. Associations of grade 3/4 neutropenia were observed with ABCC2 -1774delG (*1A), ABCG2 421C>A (Q141K) and IVS12 + 49G>T ((#) IIB) and SLCO1B1 521T>C (V174A) (*15 x 17) in the irinotecan monotherapy, while they were evident only in homozygotes of ABCB1*2, ABCG2 (#) IIB, SLCO1B1*15 x 17 in the cisplatin-combination therapy. With combinations of haplotypes/variations of two or more genes, neutropenia incidence increased, but their prediction power for grade 3/4 neutropenia is still unsatisfactory. Conclusions: Certain transporter genotypes additively increased irinotecan-induced neutropenia, but their clinical importance should be further elucidated.
What problem does this paper attempt to address?